Moya M. Daniels

Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD.

SanBio, Inc. develops regenerative therapies for neurological disorders. The firm is focused on cell therapies for neurological disorders such as stroke, traumatic brain injury, eye disease, and Parkinson's disease. Its product pipeline includes SB623 and SB618. The company was founded by Keita Mori and Toru Kawanishi in 2001 and is headquartered in Mountain View, CA.

Macrocure Ltd. is a clinical-stage biotechnology company, which engages in the development and commercialization of advanced cell therapy products. Its product, CureXcell, is an advanced wound care therapy that treat such wounds by injecting living human white blood cells that have been activate to facilitate the healing process. The company was founded by David Ben-Ami on January 14, 2008 and is headquartered in Petach Tikva, Israel.

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.